🇺🇸 FDA
Patent

US 12258333

N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

granted A61PA61P29/00

Quick answer

US patent 12258333 (N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels) held by Vertex Pharmaceuticals Incorporated expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P29/00